TDRD10

Across TCGA pan-cancer cohorts, TDRD10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TDRD10 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TDRD10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TDRD10 expression acts as an unfavorable survival marker.

BRCA, LUAD, and SCLC are the cancer types where TDRD10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.165	0.833	<.001	14	view →
LUAD	OS	Median	All	0.266	0.835	<.001	12	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
HNSC	OS	Median	II,III,IV	0.196	0.710	.023	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TDRD10–BRCA (OS)

Open the BRCA breakdown →